Mycobacterium tuberculosis-IN-9 

Mycobacterium tuberculosis-IN-9 is an orally active Mycobacterium tuberculosis BioA inhibitor with a K_i value of 0.2 nM. Mycobacterium tuberculosis-IN-9 targets the biotin biosynthesis pathway. Mycobacterium tuberculosis-IN-9 inhibits the growth of Mycobacterium tuberculosis in mouse models and is effective against both drug-sensitive and drug-resistant strains. Mycobacterium tuberculosis-IN-9 can be used for the research of tuberculosis^[1].

Mycobacterium tuberculosis-IN-9 (compound c48) potently inhibits purified Mycobacterium tuberculosis BioA enzyme with a K_i of 0.2 nM^[1].
Mycobacterium tuberculosis-IN-9 inhibits the growth of wild-type Mycobacterium tuberculosis H37Rv in biotin-free medium with an MIC₅₀ of 0.093 μM, while it shows no inhibition in medium supplemented with 2 μM biotin and has an MIC₅₀ greater than 100 μM^[1].
Mycobacterium tuberculosis-IN-9 inhibits the growth of Mycobacterium tuberculosis BioA-underexpressed strain with an MIC₅₀ of 0.014 μM^[1].
Mycobacterium tuberculosis-IN-9 inhibits the growth of Mycobacterium tuberculosis BioA-overexpressed strain with an MIC₅₀ of 0.37 μM^[1].
Mycobacterium tuberculosis-IN-9 inhibits the growth of a panel of drug-sensitive and drug-resistant Mycobacterium tuberculosis isolates with MIC_s ranging from 0.012 to 0.093 μM^[1].
Mycobacterium tuberculosis-IN-9 (0.3-30 μM; 5 min (each concentration applied twice)) weakly inhibits hERG channels in HEK-293 cells^[1].
Mycobacterium tuberculosis-IN-9 (Up to 100 μM) is not cytotoxic to HepG2 human liver cancer cells, with an IC₅₀ greater than 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

418.26

C₁₉H₁₇BrFN₃O₂

O=C(N1CCN(C2=NC=C3C(CCC3=C2)=O)CC1)C4=CC(Br)=C(C=C4)F

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liu Q, et al. Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis. J Med Chem. 2026 May 4.